GMDA Live signals | Maximize Profits with Getagraph.com

SELL 101464 min ago

@ $0.367

Issued: 13 Feb 2024 @ 16:00

Return: -91.09%

Previous signal: Feb 13 - 14:29

Previous signal: Buy

Return: 0.55 %

Live Chart Being Loaded With Signals

Commentary (5 Apr 2024 @ 16:00):

Stats
Today's Volume	23.04M
Average Volume	9.67M
Market Cap	4.34M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-31	Moch Kenneth I	Buy	200 000	Ordinary Shares
2024-01-31	Wills Stephen T	Buy	200 000	Ordinary Shares
2024-01-31	Tomasello Shawn	Buy	200 000	Ordinary Shares
2024-01-31	Adams Julian	Buy	200 000	Ordinary Shares
2024-01-31	Simantov Ronit	Buy	480 319	Ordinary Shares

INSIDER POWER
94.83
Last 90 transactions
Buy: 8 073 627 \| Sell: 418 674

Volume Correlation

Long: 0.12 (neutral)

Short: 0.82 (strong)

Signal:(73.984) Same movement expected

Gamida Cell Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gamida Cell Ltd Correlation - Currency/Commodity

0.00
( neutral )

Gamida Cell Ltd Financials

Annual	2023
Revenue:	$1.78M
Gross Profit:	$-1.69M (-94.96 %)
EPS:	$-0.570

Q4	2023
Revenue:	$1.11M
Gross Profit:	$-717 000 (-64.54 %)
EPS:	$-0.0612

Q3	2023
Revenue:	$673 000
Gross Profit:	$47 000.00 (6.98 %)
EPS:	$-0.0122

Q2	2023
Revenue:	$0
Gross Profit:	$-108 000 (0.00 %)
EPS:	$-0.310

Financial Reports:

No articles found.

Gamida Cell Ltd

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.